Working Group

« » View all

Biomarkers & Clinical Endpoints Workgroup (BCE-WG) Q4-2015

The BCE-WG identifies, develops consensus, and builds the evidence base to submit potential biomarkers and clinical endpoints that have promise in the development of new TB medical products to FDA and EMA for regulatory review and qualification in a specific context of use when applicable.

4Q, 2015 Progress:

« » View all